US2018243383A1PendingUtilityA1

Use of apc analogue for wound healing

48
Assignee: ZZ BIOTECH LLCPriority: Apr 16, 2014Filed: Feb 15, 2018Published: Aug 30, 2018
Est. expiryApr 16, 2034(~7.7 yrs left)· nominal 20-yr term from priority
Inventors:Meilang XueChristopher J. Jackson
A61P 17/02A61L 26/0066A61K 38/4866A61L 26/0076C12Y 304/21069A61K 9/0014A61K 9/0019A61L 26/008A61L 2300/252
48
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to wound repair and healing, particularly to dermal or cutaneous wounds including but not limited to acute and chronic wounds, burns and ulcers.

Claims

exact text as granted — not AI-modified
1 .- 8 . (canceled) 
     
     
         9 . A method for accelerating healing of a dermal wound including the step of contacting a dermal wound with an effective amount of 3K3A-APC, thereby accelerating the healing of the dermal wound. 
     
     
         10 . The method of  claim 9 , further comprising the step of topically administering the 3K3A-APC to the wound, thereby contacting the dermal wound with the effective amount of 3K3A-APC. 
     
     
         11 . The method of  claim 10 , wherein 3K3A-APC is topically administered to the wound in the form of a formulation selected from the group consisting of a gel, an ointment, a lotion and a spray. 
     
     
         12 . The method of  claim 9 , wherein the 3K3A-APC is administered to the wound by injection, thereby contacting the wound with an effective amount of 3K3A-APC. 
     
     
         13 . The method of  claim 9 , wherein the dermal wound is not characterised by significant apoptosis, or otherwise does not arise from apoptosis. 
     
     
         14 . The method of  claim 10 , wherein the dermal wound is not characterised by significant apoptosis, or otherwise does not arise from apoptosis. 
     
     
         15 . The method of  claim 12 , wherein the dermal wound is not characterised by significant apoptosis, or otherwise does not arise from apoptosis. 
     
     
         16 . The method of  claim 10 , wherein the dermal wound is a chronic dermal wound. 
     
     
         17 . The method of  claim 12 , wherein the dermal wound is a chronic dermal wound. 
     
     
         18 . The method of  claim 10 , wherein the dermal wound is an acute dermal wound. 
     
     
         19 . The method of  claim 12 , wherein the dermal wound is an acute dermal wound. 
     
     
         20 . The method of  claim 10 , wherein the wound is a burn, incision, laceration, abrasion, puncture or ulcer. 
     
     
         21 . The method of  claim 12 , wherein the wound is a burn, incision, laceration, abrasion, puncture or ulcer. 
     
     
         22 . The method of  claim 10 , wherein the 3K3A-APC is provided in an amount of 250 μg or 500 μg. 
     
     
         23 . The method of  claim 12 , wherein the 3K3A-APC is provided in an amount of 250 μg or 500 μg. 
     
     
         24 . The method of  claim 10 , wherein 3K3A-APC concentration at the dermal wound is at least 2 times higher than APC basal level. 
     
     
         25 . The method of  claim 12 , wherein 3K3A-APC concentration at the dermal wound is at least 2 times higher than APC basal level.

Join the waitlist — get patent alerts

Track US2018243383A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.